Enliven Therapeutics Inc

During our last fiscal quarter, the following director(s) and officer(s), as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, as follows:

On November 15, 2024, Samuel Kintz, our President and Chief Executive Officer, a director, and an officer as defined in Rule 16a-1(f), as trustee for The Kintz & Egan Trust, dated March 30, 2019, adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408 providing for the sale from time to time of an aggregate of up to 400,000 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 13, 2026, or earlier if all transactions under the trading arrangement are completed.

On November 15, 2024, Joseph P. Lyssikatos, our Chief Scientific Officer and an officer as defined in Rule 16a-1(f), as trustee for The Lyssikatos Revocable Trust, dated December 15, 2011, adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408 providing for the sale from time to time of an aggregate of up to 400,000 sharesof our common stock. The trading arrangementis intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 17, 2026, or earlier if all transactions under the trading arrangement are completed.

On November 15, 2024, Richard Heyman, Ph.D., adirector, as trustee for The 4th Amendment and Restatement of Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016, adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408 providing for the sale from time to time of an aggregate of up to 49,160 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 13, 2026, or earlier if all transactions under the trading arrangement are completed.

On November 15, 2024, RAHD Capital, LLC, adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408 providing for the sale from time to time of an aggregate of up to 5,420 shares of our common stock. Richard Heyman, Ph.D., adirector, is the managing member of RAHD Capital, LLC. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 13, 2026, or earlier if all transactions under the trading arrangement are completed.

No other officers or directors, as defined in Rule 16a-1(f), adopted and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the last fiscal quarter.